MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.05 -0.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.04

Max

1.05

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+337.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-9.2M 117M
Eelmine avamishind	1.99
Eelmine sulgemishind	1.05

Uudiste sentiment

By Acuity

50%

187 / 370 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. jaan 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. jaan 2026, 21:43 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9. jaan 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9. jaan 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9. jaan 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9. jaan 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9. jaan 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9. jaan 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9. jaan 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9. jaan 2026, 19:58 UTC

Omandamised, ülevõtmised, äriostud

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9. jaan 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9. jaan 2026, 19:38 UTC

Omandamised, ülevõtmised, äriostud

Wolters Kluwer Acquires StandardFusion >WTKWY

9. jaan 2026, 19:31 UTC

Tulu

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9. jaan 2026, 19:28 UTC

Tulu

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9. jaan 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9. jaan 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

9. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. jaan 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. jaan 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9. jaan 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9. jaan 2026, 17:05 UTC

Tulu

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9. jaan 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9. jaan 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. jaan 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

337.74% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 337.74%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

187 / 370 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.